

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/666,095	09/18/2003	Robert P. Hammer	Hammer 0212.1	6953	
25547	7590 04/01/2005	•	EXAM	EXAMINER	
PATENT DEPARTMENT TAYLOR, PORTER, BROOKS & PHILLIPS, L.L.P			RUSSEL, JI	RUSSEL, JEFFREY E	
P.O. BOX 2471			ART UNIT	PAPER NUMBER .	
BATON ROUGE, LA 70821-2471		1654	·		

DATE MAILED: 04/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/666,095	HAMMER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Jeffrey E. Russel	1654			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONED	ely filed  will be considered timely. the mailing date of this communication.  O (35 U.S.C. § 133).			
Status					
<ul> <li>1) Responsive to communication(s) filed on 18 Section 18 Section 18 FINAL.</li> <li>2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under Expression 19 Section 19 Sect</li></ul>	action is non-final. ce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-50 is/are pending in the application.  4a) Of the above claim(s) is/are withdraw  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) 1-50 are subject to restriction and/or experience.  Application Papers  9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the consequence of the c	election requirement.  c.  epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is objected to by the drawing(s) is o	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:				

Art Unit: 1654

1. This application contains claims directed to the following patentably distinct species of the claimed invention:

The twelve peptidyl sequences recited in instant claim 1 are patentably distinct from one another because of their materially different amino acid sequences. In addition, compounds which inhibit the toxicity of an amyloid protein or an amyloid peptide wherein the amyloid protein and amyloid peptide are selected from those recited in instant claims 7-18 are patentably distinct from one another because of the materially different amino acid sequences of the amyloid proteins and the amyloid peptides (the amino acid sequences of the claimed compounds are based upon the amino acid sequences of the amyloid proteins and the amyloid peptides - see, e.g., pages 11-13 of the specification).

Applicant is required under 35 U.S.C. 121 to elect: (1) a single peptidyl sequence from among those recited in claim 1; and (2) a single amyloid protein or amyloid peptide from among those recited in claims 7-18 upon which the claimed compounds are to be modeled; for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 7-22, and 28-50 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

2. In addition to the above election of species requirement, the following restriction requirement is imposed:

Claims 2-6 and 23-27 are generic to a plurality of disclosed patentably distinct sequences comprising: SEQ ID NOS:4, 5, 6, and 7. These sequences are patentably distinct, each from the other, because of their materially different amino acid sequences. Searching all of the claimed sequences would constitute an undue burden on the examiner because different sequence searches would be required for each of the claimed sequences. Applicant is required under 35 U.S.C. 121 to elect a single disclosed sequence, even though this requirement is traversed.

Should applicant traverse on the ground that the sequences are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the sequences to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

This is not a species election, but a holding that the sequences are patentably distinct, one from the other.

Application/Control Number: 10/666,095 Page 4

Art Unit: 1654

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Bruce Campell can be reached at (571) 272-0974. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.

Jeffrey E. Russel
Primary Patent Examiner
Art Unit 1654

JRussel March 25, 2005